Clinical Trial Update: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of a fixed-dose regimen of Sofosbuvir/Velpatasvir/Voxilaprevir with or without Ribavirin in adults with chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir/Voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-09-14